Abbott Laboratories (NYSE:ABT) has been given an average recommendation of “Buy” by the twenty-three research firms that are currently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $66.12.
Several research firms recently commented on ABT. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price target on the stock in a research report on Tuesday, October 31st. Royal Bank of Canada reissued a “buy” rating and set a $65.00 price target on shares of Abbott Laboratories in a research report on Tuesday, January 9th. BMO Capital Markets raised Abbott Laboratories from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $58.00 to $65.00 in a research report on Tuesday, December 12th. Morgan Stanley raised Abbott Laboratories from an “equal weight” rating to an “overweight” rating and set a $67.00 price target on the stock in a research report on Tuesday, January 2nd. Finally, JPMorgan Chase & Co. raised Abbott Laboratories from a “neutral” rating to an “overweight” rating and set a $60.00 price target on the stock in a research report on Tuesday, January 2nd.
In other Abbott Laboratories news, Chairman Miles D. White sold 276,886 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $54.41, for a total transaction of $15,065,367.26. Following the sale, the chairman now directly owns 3,677,913 shares in the company, valued at approximately $200,115,246.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian J. Blaser sold 23,866 shares of Abbott Laboratories stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $55.55, for a total value of $1,325,756.30. Following the sale, the insider now owns 146,387 shares in the company, valued at $8,131,797.85. The disclosure for this sale can be found here. Insiders have sold a total of 374,458 shares of company stock worth $20,752,706 over the last 90 days. 0.76% of the stock is owned by company insiders.
Abbott Laboratories (NYSE ABT) opened at $57.64 on Wednesday. The firm has a market capitalization of $99,927.90, a PE ratio of 221.70, a PEG ratio of 1.72 and a beta of 1.55. Abbott Laboratories has a 52 week low of $42.31 and a 52 week high of $64.60. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72.
Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.01. The business had revenue of $7.59 billion for the quarter, compared to analyst estimates of $7.38 billion. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The company’s revenue was up 42.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.65 EPS. sell-side analysts anticipate that Abbott Laboratories will post 2.86 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be issued a dividend of $0.28 per share. The ex-dividend date is Thursday, January 11th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.27. This represents a $1.12 annualized dividend and a yield of 1.94%. Abbott Laboratories’s payout ratio is currently 430.79%.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/14/abbott-laboratories-abt-given-consensus-recommendation-of-buy-by-analysts.html.
Abbott Laboratories Company Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.